Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.

The Journal of dermatological treatment - 1 Dec 2013

Agarwala Manoj Kumar, George Renu, Mathews Vikram, Balasubramanian Poonkuzhali, Thomas Meera, Nair Sheila

Abstract excerpt

BACKGROUND: Mastocytosis is a sporadic disease characterized by an abnormal accumulation of mast cells (MCs) in single or multiple organs. It has a heterogeneous clinical picture which is a reflection of underlying tissue MC burden, mediators released and the organs involved. Here, the authors report significant symptomatic, cutaneous and systemic response to imatinib in a case of childhood onset indolent D816V...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Mastocytosis, Systemic

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Young Adult

Source

Identifiers

PMID: 23659595
DOI: 10.3109/09546634.2013.802274

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.PMID 23659595Read ↗

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutationSemantic proximity Read ↗

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.Semantic proximity Read ↗

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literatureSemantic proximity Read ↗

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Mastocytosis: a comprehensive insight.Semantic proximity Read ↗

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.Semantic proximity Read ↗

Pediatric Mastocytosis: Recognition and Management.Semantic proximity Read ↗

[Current concepts and treatment advances in systemic mastocytosis].Semantic proximity Read ↗

Management of Mastocytosis and Mast Cell Activation in Children.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.